Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): Its' Correlation Factors and an Educational Intervention Programme
NCT04930185 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600
Last updated 2021-06-18
Summary
The COVID-19 pandemic has spread to over 200 countries worldwide and is still on the rise in 88 countries. Unfortunately, Malaysia is not the exception and registered 340,642 COVID-19 cases till 29 March 2021 since the outbreak of the pandemic.
COVID-19 virus can be transmitted from an infected person to others through droplets when coughing or sneezing as well as by touching objects infected with the virus. Although precautionary measures, which include the regular and mandatory use of face masks, reducing crowds, and physical distancing, have been widely encouraged by WHO and the Malaysian government, getting COVID-19 vaccination remain the way forward to curb the wide spread of the virus and to return to the normal.
However, the public awareness on the importance of getting vaccinated is still low with high level of vaccination hesitance and refusal. In Malaysia, this challenge is compounded further due to a lack of COVID-19 vaccination educational intervention programme in Bahasa Malaysia to educate the predominantly larger group in the population who are more conversant in ther national language. In order to improve the acceptance rate towards the COVID-19 vaccination in Malaysia, it is imperative to design a comprehensive intervention program that will increase the awareness and knowledge with regards to the efficacy of the COVID-19 vaccine as a solution in overcoming this pandemic.
With this in mind, this study aims to identify the correlational factors of COVID-19 and develop an educational intervention programme on COVID-19 vaccination and thereafter, assess the effectiveness of this educational intervention programme.
Conditions
- COVID-19 Vaccination
Interventions
- BEHAVIORAL
-
Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
Participants will be receiving the pamphlet about the COVID-19 vaccination information during the intervention. They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention. Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.
- BEHAVIORAL
-
Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
Participants will be receiving the webinar last for half an hour about the COVID-19 vaccination information during the intervention. They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention. Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.
- BEHAVIORAL
-
Reducing Vaccine Hesitancy (VH) And Vaccine Refusal (VR): An Educational Intervention Programme
Participants will be receiving the SMS about the COVID-19 vaccination information during the intervention. They will received 3 different sets of questionnaire to measured their level of vaccine hesitancy and vaccine refusal in 3 different time points: (a) before intervention, (b) after the intervention, and (c) 3 months after the intervention. Data cleansing will be conducted based on the per-protocol analysis. Pre-protocol is a comparison of treatment groups that includes only those patients who completed the treatment originally allocated.
Sponsors & Collaborators
-
Sunway University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-09-01
- Primary Completion
- 2022-12-31
- Completion
- 2023-01-31
Countries
- Malaysia
Study Locations
More Related Trials
-
Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Enteric Fever Vaccine
NCT04349553 ·Status: COMPLETED ·Phase: PHASE1
-
COVIDVaxStories: Randomized Trial to Reduce COVID-19 Vaccine Hesitancy in Populations of Color
NCT06297876 ·Status: COMPLETED ·Phase: NA
-
Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters
NCT06074237 ·Status: COMPLETED ·Phase: NA
-
Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
NCT03561181 ·Status: COMPLETED ·Phase: PHASE1
-
Screening for Hesitancy to Optimize Talk
NCT02708745 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)
NCT05107557 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old
NCT04865497 ·Status: COMPLETED ·Phase: PHASE2
-
Impact on Quality of Hospital Care During Pre- and Post- Rotavirus (RV) Vaccination Introduction in Belgium
NCT01592838 ·Status: COMPLETED
-
Novelty, Conformity and Trust in COVID-19 Vaccines
NCT04693689 ·Status: COMPLETED ·Phase: NA
-
Vaccine Attitudes and Practices of Hospital Specialists
NCT03403114 ·Status: COMPLETED
-
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
NCT04816643 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates
NCT03462108 ·Status: COMPLETED ·Phase: PHASE1
-
The Impact of Vaccination on Severity of Illness in COVID-19
NCT04912700 ·Status: COMPLETED
-
Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine
NCT00109304 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
NCT06337071 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa
NCT04658914 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
NCT05546502 ·Status: COMPLETED ·Phase: PHASE3
-
Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 Years
NCT05112913 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Improving Vaccinations for Young Children (IVY)
NCT04203277 ·Status: COMPLETED ·Phase: NA
-
Impact of PACV Administration on Vaccine Hesitancy
NCT04450940 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom
NCT03632720 ·Status: COMPLETED ·Phase: PHASE3
-
Development of a Live Attenuated Rotavirus Vaccine as a Human Infection Challenge Model
NCT04123119 ·Status: COMPLETED ·Phase: NA
-
Tailoring of Vaccine-Focused Messages: Moral Foundations
NCT02851459 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study With QIVc in Pediatric Subjects
NCT03932682 ·Status: COMPLETED ·Phase: PHASE3
-
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children
NCT03680417 ·Status: COMPLETED ·Phase: PHASE4